Article Sidebar
Published:
Jun 9, 2023DOI:
10.4314/tjpr.v22i2.7Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
NR4A1 alleviates the toxicity in neural stem cells induced by propofol in early life by regulating AMPK pathway
Abstract
Purpose: To examine the association of propofol (PRO) with related key genes that may serve as potential biomarkers for alleviation of PRO-induced toxicity in neural stem cells (NSCs).
Methods: Differentially expressed genes (DEGs) were screened based on GEO database, using the analysis platform of Metaboanalyst, GEO2R, DAVID and Ehbio. NSCs were purchased and treated with 3 μM of propofol (PRO). NR4A1 was transfected into NSCs, and the NR4A1 expression, apoptosis-related protein and AMPK pathway-related protein were determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting. Cell viability and apoptosis were evaluated by methylthiazolyldiphenyl-tetrazolium bromid (MTT) assay and flow cytometry.
Results: A total of 278 DEGs were analyzed on GSE106799 microarray, and finally screened for differentially expressed down-regulated gene, NR4A1, which is a hubgene. NR4A1 expression decreased in PRO-induced NSCs. Furthermore, NR4A1 attenuated the PRO-induced decrease in the viability of NSCs and the increase in apoptosis. Moreover, NR4A1 increased p-AMPK/AMPK level.
Conclusion: NR4A1 attenuates the toxicity in NSCs induced by PRO by regulating AMPK pathways, and thus provides a theoretical basis for the treatment of nerve damage caused by anesthetics.
